Comparative Pharmacology
Head-to-head clinical analysis: PREMPHASE PREMARIN CYCRIN 14 14 versus PREMPHASE 14 14.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PREMPHASE PREMARIN CYCRIN 14 14 versus PREMPHASE 14 14.
PREMPHASE (PREMARIN;CYCRIN 14/14) vs PREMPHASE 14/14
Head-to-head clinical comparison of therapeutic indices and safety profiles.
PREMPHASE combines conjugated estrogens (PREMARIN) and medroxyprogesterone acetate (CYCRIN). Estrogens act by binding to nuclear estrogen receptors (ERα and ERβ), which regulate gene transcription and produce effects in tissues such as the endometrium, breast, and bone. Medroxyprogesterone acetate is a progestin that induces secretory changes in the endometrium and reduces the risk of endometrial hyperplasia associated with estrogen therapy.
Conjugated estrogens (CE) bind to estrogen receptors (ERα and ERβ), modulating gene transcription and non-genomic signaling pathways to induce estrogenic effects. Medroxyprogesterone acetate (MPA) is a progestin that binds to progesterone receptors, suppressing endometrial proliferation and counteracting estrogen-induced endometrial hyperplasia. The combination provides hormone replacement therapy with reduced risk of endometrial cancer.
Treatment of moderate to severe vasomotor symptoms associated with menopauseTreatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopausePrevention of postmenopausal osteoporosis
Treatment of moderate to severe vasomotor symptoms associated with menopauseTreatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with menopausePrevention of postmenopausal osteoporosis
One tablet daily (conjugated estrogens 0.625 mg/medroxyprogesterone acetate 5 mg) for 14 days, followed by one tablet daily (conjugated estrogens 0.625 mg) for 14 days; continuous cycling. Oral administration.
One tablet orally once daily, each tablet contains conjugated estrogens 0.625 mg and medroxyprogesterone acetate 5 mg.
None Documented
None Documented
Conjugated estrogens: terminal half-life 10–24 h (accumulation with daily dosing). MPA: terminal half-life 12–33 h (mean ∼17 h).
Conjugated estrogens have a terminal elimination half-life of 12-24 hours for conjugated equine estrogens; medroxyprogesterone acetate has a half-life of 12-17 hours. Steady-state is reached within 5-7 days.
Conjugated estrogens are extensively metabolized in the liver via glucuronidation and sulfation, with enterohepatic recirculation. Medroxyprogesterone acetate is primarily metabolized via hydroxylation and reduction by CYP3A4, forming multiple metabolites.
Conjugated estrogens are primarily metabolized in the liver via cytochrome P450 3A4 (CYP3A4) and other CYP enzymes, with conjugation (glucuronidation and sulfation) to inactive metabolites. Medroxyprogesterone acetate is extensively metabolized in the liver, primarily via hydroxylation and conjugation, with CYP3A4 playing a major role. Both undergo enterohepatic recirculation and are excreted in urine and feces.
Conjugated estrogens and MPA are primarily excreted in urine (∼90% as glucuronide and sulfate conjugates) and feces (∼10% as unabsorbed drug and biliary metabolites).
Conjugated estrogens are excreted primarily in urine (≥90%) as glucuronide and sulfate conjugates; medroxyprogesterone acetate is extensively metabolized and excreted in urine (≤60%) and feces (≤30%) as metabolites.
Conjugated estrogens: 50–80% bound to albumin and sex hormone-binding globulin (SHBG). MPA: 90–95% bound to albumin, not to SHBG or corticosteroid-binding globulin.
Conjugated estrogens: ~50-80% bound to albumin and sex hormone-binding globulin (SHBG); medroxyprogesterone acetate: ~85-90% bound to albumin (not SHBG).
Conjugated estrogens: 1–2 L/kg (extensive tissue distribution). MPA: 0.5–1.0 L/kg (moderate distribution into adipose and liver).
Conjugated estrogens: Vd ~1-2 L/kg, distributed widely into tissues including breast, uterine, and adipose tissue; medroxyprogesterone acetate: Vd ~0.5-1 L/kg.
Conjugated estrogens: oral, 40–50% (extensive first-pass glucuronidation). MPA: oral, 100% (almost completely absorbed; minimal first-pass effect).
Oral bioavailability of conjugated estrogens is 60-80%; medroxyprogesterone acetate is 100% (oral). Transdermal or vaginal routes for estrogens alone show 10-20% absorption vs oral.
No specific dose adjustment required for renal impairment; use with caution in severe renal disease due to potential fluid retention.
No specific dose adjustment recommended; use with caution in patients with renal impairment.
Contraindicated in Child-Pugh class C cirrhosis; in Child-Pugh class A or B, use lowest effective dose and monitor liver function; avoid in acute hepatic disease.
Contraindicated in patients with severe hepatic disease (Child-Pugh class C); use with caution in mild to moderate impairment (Child-Pugh class A or B) with dose reduction as clinically indicated.
Not indicated for use in pediatric patients; safety and efficacy not established.
Not indicated for use in pediatric patients.
Use lowest effective dose for shortest duration; increased risk of thromboembolic events, stroke, and dementia; consider alternative therapies.
No specific dose adjustment; monitor for adverse effects such as thromboembolic events and malignancy.
Estrogens with or without progestins should not be used to prevent cardiovascular disease or dementia. There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens. The Women's Health Initiative (WHI) substudy reported increased risks of myocardial infarction, stroke, invasive breast cancer, pulmonary emboli, and deep vein thrombosis in postmenopausal women (50-79 years of age) during 5.6 years of treatment with conjugated equine estrogens (0.625 mg) combined with medroxyprogesterone acetate (2.5 mg) relative to placebo. The WHI Memory Study (WHIMS) reported an increased risk of developing probable dementia in postmenopausal women 65 years of age or older during 4 years of treatment with CE (0.625 mg) combined with MPA (2.5 mg) relative to placebo.
Estrogen-plus-progestin therapy should not be used for the prevention of cardiovascular disease. The Women's Health Initiative (WHI) study reported increased risks of myocardial infarction, stroke, invasive breast cancer, pulmonary emboli, and deep vein thrombosis in postmenopausal women (50-79 years) treated with daily oral CE 0.625 mg/MPA 2.5 mg. Risks are dose- and duration-dependent.
["Cardiovascular disorders: increased risk of stroke, DVT, pulmonary embolism, and myocardial infarction","Malignant neoplasms: increased risk of endometrial cancer (if uterus intact) and breast cancer","Dementia: increased risk of probable dementia in women ≥65 years","Gallbladder disease","Hypercalcemia in patients with breast cancer and bone metastases","Visual abnormalities: retinal vascular thrombosis","Fluid retention","Elevated blood pressure","Hypertriglyceridemia"]
["Cardiovascular disorders: Increased risk of stroke and DVT; discontinue if thrombosis suspected.","Malignancy: Increased risk of breast cancer (especially with combined therapy), endometrial cancer (estrogen-alone therapy), and ovarian cancer; perform regular breast exams and mammography.","Dementia: Possible increased risk in women ≥65 years; avoid use for prevention.","Gallbladder disease: Increased risk requiring cholecystectomy.","Hypercalcemia: May occur in women with breast cancer and bone metastases.","Visual abnormalities: Discontinue if sudden partial or complete vision loss occurs (consider retinal vascular thrombosis).","Fluid retention: Use with caution in conditions exacerbated by fluid retention (e.g., cardiac/renal dysfunction).","Hypothyroidism: May increase thyroid-binding globulin levels, requiring dose adjustment of thyroid hormone.","Triglyceride elevations: Use with caution in patients with hypertriglyceridemia; monitor levels."]
["Undiagnosed abnormal genital bleeding","Known, suspected, or history of breast cancer","Known or suspected estrogen-dependent neoplasia","Active DVT, PE, or history of these conditions","Active arterial thromboembolic disease (e.g., stroke, MI) or history","Known anaphylactic reaction or angioedema to PREMPHASE","Known liver impairment or disease","Known or suspected pregnancy"]
["Undiagnosed abnormal genital bleeding","Known, suspected, or history of breast cancer","Known or suspected estrogen-dependent neoplasia (e.g., endometrial cancer)","Active or history of deep vein thrombosis, pulmonary embolism, or thrombophlebitis","Active or history of arterial thromboembolic disease (e.g., stroke, MI)","Known protein C, protein S, or antithrombin deficiency (or other thrombophilic disorders)","Known or suspected pregnancy","Liver dysfunction or disease (e.g., active hepatitis, cirrhosis)","Hypersensitivity to conjugated estrogens, medroxyprogesterone acetate, or any ingredients"]
Data Pending Review
Data Pending Review
No specific food interactions; advise consistent intake of calcium and vitamin D (1000-1500 mg calcium/day; 600-800 IU vitamin D/day) for bone health. Avoid grapefruit juice if on concurrent statins or other CYP3A4 substrates (grapefruit may affect estrogen metabolism).
No specific food interactions are documented. However, grapefruit juice may theoretically increase estrogen levels by inhibiting CYP3A4; consider moderate intake. Maintain adequate calcium and vitamin D intake for bone health. Avoid alcohol in excess as it may exacerbate menopausal symptoms and increase osteoporosis risk.
First trimester: epidemiological studies suggest a small increased risk of non-cardiac congenital anomalies (e.g., limb defects) and possible neural tube defects from estrogen exposure. Second and third trimesters: exposure may cause urogenital tract abnormalities in male and female offspring (e.g., vaginal adenosis, clear cell adenocarcinoma in females; hypospadias in males). Use is contraindicated in pregnancy.
PREMARIN (conjugated estrogens) and medroxyprogesterone acetate (MPA) are contraindicated in pregnancy. Estrogen use during first trimester is associated with urogenital tract abnormalities (e.g., hypospadias) and possible transgenerational effects. Second and third trimester exposure may increase risk of fetal reproductive tract abnormalities (e.g., vaginal adenosis, clear cell adenocarcinoma) from DES-like effects, though risk is lower with current formulations. MPA is a progestin with potential androgenic effects; animal studies show feminization of male fetuses and masculinization of female fetuses at high doses. Overall, use in pregnancy is contraindicated.
Estrogens and medroxyprogesterone acetate are excreted in human milk in small amounts. M/P ratio not precisely defined. May reduce milk production and composition. Not recommended during breastfeeding due to potential adverse effects on the infant (e.g., estrogenic effects, jaundice).
Estrogens and progestins are excreted in human milk in small amounts. Milk-to-plasma ratio (M/P) for conjugated estrogens is approximately 0.4-0.6; for MPA, M/P ratio is about 0.3-0.5. Exposed infants may experience jaundice, breast enlargement, or hormonal effects. PREMPHASE may reduce milk production and quality. Breastfeeding is generally not recommended during therapy; if used, monitor infant for adverse effects.
No dose adjustment applicable as PREMPHASE is contraindicated in pregnancy; pharmacokinetic changes (increased plasma volume, altered hepatic metabolism) could potentially affect drug levels, but use is not recommended.
No dose adjustments can be recommended as PREMPHASE is contraindicated in pregnancy. Pharmacokinetic changes in pregnancy (increased hepatic clearance, increased plasma volume) would theoretically require higher doses, but due to unacceptable fetal risks, the drug should not be used.
Category C
Category C
Premphase is a cyclic estrogen/progestin regimen for postmenopausal women with an intact uterus. The 14/14 regimen: conjugated estrogens 0.625 mg daily continuously plus medroxyprogesterone acetate 5 mg from days 15–28. Assess endometrial status before starting; annual mammograms and pelvic exams required. Avoid in women with known or suspected pregnancy, breast cancer, or active thromboembolic disease. Consider risk of cardiovascular events, stroke, and dementia with prolonged use. Taper rather than abruptly discontinue to avoid withdrawal bleeding.
Premphase 14/14 (conjugated estrogens 0.625 mg/medroxyprogesterone acetate 5 mg) is a continuous-sequential hormone therapy regimen: estrogen daily, with progestin added on days 15–28 of a 28-day cycle. Use only in women with an intact uterus. Avoid in women with known or suspected pregnancy, undiagnosed abnormal genital bleeding, breast cancer, estrogen-dependent neoplasia, active DVT/PE, or history of thrombophlebitis. Initiate at the lowest effective dose for the shortest duration. Monitor for endometrial hyperplasia, breast tenderness, and thromboembolic events. Consider alternative therapies for menopausal symptoms if cardiovascular or breast cancer risk is high. The progestin component reduces the risk of endometrial cancer associated with unopposed estrogen.
Take the pink tablet daily for days 1–14 of each cycle, then the light-blue tablet daily for days 15–28. Bleeding may occur mid-cycle or during placebo days.Report any abnormal vaginal bleeding, chest pain, leg swelling, severe headache, or vision changes immediately.Do not use if pregnant or planning pregnancy; use effective contraception if needed.Smoking increases risk of cardiovascular side effects; avoid smoking.Annual breast and pelvic exams are mandatory; perform monthly breast self-exams.
Take one tablet daily at the same time each day. The regimen is 14 days of estrogen-only tablets (maroon) followed by 14 days of combination estrogen-progestin tablets (light blue).Report any unusual vaginal bleeding, breast lumps, or signs of thrombosis (sudden chest pain, shortness of breath, leg swelling/pain) immediately.Do not smoke while taking this medication; smoking increases the risk of blood clots and stroke.Inform your healthcare provider about all medications you take, including herbal supplements, as some may interact.Serious risks include endometrial cancer, cardiovascular events (heart attack, stroke, DVT/PE), and breast cancer. Discuss individual risks vs. benefits with your doctor.This medication is not for use during pregnancy or breastfeeding.If you miss a dose, take it as soon as remembered; if near next dose, skip the missed dose. Do not double dose.Store at room temperature away from moisture and heat.